Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01446809 · ClinicalTrials.gov registry record · NA
Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma
A NA study, sponsored by University of Washington.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
NCT01446809 is a NA study that has completed, run by University of Washington. The registered enrollment target is 23 participants.
The verdict
NCT01446809, a NA study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
Study Summary
This randomized pilot clinical trial studies pazopanib hydrochloride followed by chemotherapy and surgery in treating patients with soft tissue sarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes that are needed for cell growth and may also stop the growth of soft tissue sarcoma by blocking blood flow to the tumor. Giving pazopanib hydrochloride and chemotherapy before surgery may make the tumor smaller and reduce the amount of tissue that needs to be removed.
Interventions
- RADIATION External Beam Radiation Therapy
- OTHER Laboratory Biomarker Analysis
- DRUG Doxorubicin Hydrochloride
- DRUG Ifosfamide
- DRUG Pazopanib Hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2012-04 |
| Est. Completion | 2019-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01446809
The ClinicalTrials.gov registry entry for NCT01446809 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which External Beam Radiation Therapy is the first listed.
NCT01446809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01446809 about?
NCT01446809 is a clinical study titled "Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma". This randomized pilot clinical trial studies pazopanib hydrochloride followed by chemotherapy and surgery in treating patients with soft tissue sarcoma. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes that are needed for cell growth and may also stop the gr...
What is the current status of trial NCT01446809?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2012-04. Estimated completion is 2019-01.
What interventions are being tested in trial NCT01446809?
The interventions under investigation include: External Beam Radiation Therapy (RADIATION), Laboratory Biomarker Analysis (OTHER), Doxorubicin Hydrochloride (DRUG), Ifosfamide (DRUG), Pazopanib Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT01446809?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.